BG104434A - 2-halo-6-o-substituted ketolide derivatives - Google Patents

2-halo-6-o-substituted ketolide derivatives

Info

Publication number
BG104434A
BG104434A BG104434A BG10443400A BG104434A BG 104434 A BG104434 A BG 104434A BG 104434 A BG104434 A BG 104434A BG 10443400 A BG10443400 A BG 10443400A BG 104434 A BG104434 A BG 104434A
Authority
BG
Bulgaria
Prior art keywords
halo
ketolide derivatives
substituted ketolide
compound
pharmaceutically acceptable
Prior art date
Application number
BG104434A
Other languages
Bulgarian (bg)
Other versions
BG64707B1 (en
Inventor
Ly T. Phan
Yat S. Or
Daniel T. Chu
Jacob J. Plattner
Yan Chen
Richard F. Clark
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG104434A publication Critical patent/BG104434A/en
Publication of BG64707B1 publication Critical patent/BG64707B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formulae compositions comprising of a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for their preparation. 14 claims
BG104434A 1997-10-29 2000-05-15 2-halo-6-o-substituted ketolide derivatives BG64707B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95988197A 1997-10-29 1997-10-29
US15423998A 1998-09-16 1998-09-16

Publications (2)

Publication Number Publication Date
BG104434A true BG104434A (en) 2001-01-31
BG64707B1 BG64707B1 (en) 2005-12-30

Family

ID=26851273

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104434A BG64707B1 (en) 1997-10-29 2000-05-15 2-halo-6-o-substituted ketolide derivatives

Country Status (25)

Country Link
EP (1) EP1027362B1 (en)
JP (1) JP2001521039A (en)
KR (1) KR100536420B1 (en)
CN (1) CN1240707C (en)
AR (1) AR015994A1 (en)
AT (1) ATE298760T1 (en)
AU (1) AU751448B2 (en)
BG (1) BG64707B1 (en)
BR (1) BR9813319A (en)
CA (1) CA2307788C (en)
CO (1) CO4990960A1 (en)
CZ (1) CZ300063B6 (en)
DE (1) DE69830739T2 (en)
DK (1) DK1027362T3 (en)
ES (1) ES2244094T3 (en)
HK (1) HK1031383A1 (en)
HU (1) HUP0004282A3 (en)
IL (1) IL135519A0 (en)
NO (1) NO20002190L (en)
NZ (1) NZ503822A (en)
PL (1) PL191453B1 (en)
PT (1) PT1027362E (en)
SK (1) SK286397B6 (en)
TR (1) TR200001142T2 (en)
WO (1) WO1999021871A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784682B1 (en) 1998-10-15 2002-12-06 Hoechst Marion Roussel Inc NOVEL 2-HALOGEN DERIVATIVES OF 5-0-DESOSAMINYLERYTHRONOLIDE A, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
USRE39743E1 (en) * 1998-10-15 2007-07-24 Aventis Pharma S.A. 2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use
WO2000063224A2 (en) * 1999-04-16 2000-10-26 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
US6514944B2 (en) 1999-04-16 2003-02-04 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6451768B1 (en) 1999-04-16 2002-09-17 Kosan Biosciences, Inc. Macrolide antiinfective agents
CA2391297C (en) * 1999-12-02 2009-01-06 Abbott Laboratories 6-o-alkyl-2-nor-2-substituted ketolide derivatives
US6569836B2 (en) 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
JP2001261694A (en) 2000-03-06 2001-09-26 Pfizer Prod Inc Ketolide antibiotic
US6605707B1 (en) * 2000-03-23 2003-08-12 Abbott Laboratories Process for the preparation of 6-O-propargyl erythromycin derivatives
DE60104240T2 (en) 2000-06-30 2005-08-04 Pfizer Products Inc., Groton Macrolide antibiotics
US6472372B1 (en) * 2000-12-06 2002-10-29 Ortho-Mcneil Pharmaceuticals, Inc. 6-O-Carbamoyl ketolide antibacterials
US6713455B2 (en) 2001-09-17 2004-03-30 Ortho-Mcneil Pharmaceutical, Inc. 6-O-carbamate-11,12-lacto-ketolide antimicrobials
CA2469304A1 (en) 2001-12-05 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. 6-o acyl ketolide antibacterials
MXPA04007883A (en) * 2002-02-13 2004-11-26 Abbott Lab Macrolide antibacterial compounds.
WO2003090761A1 (en) * 2002-04-25 2003-11-06 Abbott Laboratories 9-oxime macrolide antibacterials
CA2483220A1 (en) * 2002-04-25 2003-11-06 Abbott Laboratories Oxolide antibacterials
WO2004078771A1 (en) * 2003-03-07 2004-09-16 Taisho Pharmaceutical Co., Ltd. 2-fluoro-6-o-substituted ketolide derivative
JP2007254285A (en) * 2004-03-16 2007-10-04 Taisho Pharmaceut Co Ltd 2-fluoro-6-o-substituted ketolide derivative
WO2010136971A1 (en) * 2009-05-27 2010-12-02 Wockhardt Research Centre Ketolide compounds having antimicrobial activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
KR0166996B1 (en) * 1992-04-22 1999-01-15 우에하라 아키라 5-o-desosaminylerythronolide-a derivative
FR2742757B1 (en) * 1995-12-22 1998-01-30 Roussel Uclaf NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS

Also Published As

Publication number Publication date
BR9813319A (en) 2000-08-22
KR20010015793A (en) 2001-02-26
DE69830739T2 (en) 2006-04-20
WO1999021871A1 (en) 1999-05-06
CN1240707C (en) 2006-02-08
KR100536420B1 (en) 2005-12-16
AU751448B2 (en) 2002-08-15
CN1283199A (en) 2001-02-07
ATE298760T1 (en) 2005-07-15
NO20002190L (en) 2000-06-29
NO20002190D0 (en) 2000-04-27
HUP0004282A3 (en) 2001-10-29
PL191453B1 (en) 2006-05-31
IL135519A0 (en) 2001-05-20
CO4990960A1 (en) 2000-12-26
NZ503822A (en) 2002-12-20
PT1027362E (en) 2005-08-31
CA2307788C (en) 2008-05-20
TR200001142T2 (en) 2000-09-21
AU1288199A (en) 1999-05-17
CZ20001525A3 (en) 2000-10-11
SK6332000A3 (en) 2000-09-12
ES2244094T3 (en) 2005-12-01
SK286397B6 (en) 2008-09-05
DE69830739D1 (en) 2005-08-04
DK1027362T3 (en) 2005-10-31
HUP0004282A2 (en) 2001-04-28
CA2307788A1 (en) 1999-05-06
JP2001521039A (en) 2001-11-06
HK1031383A1 (en) 2001-06-15
AR015994A1 (en) 2001-05-30
CZ300063B6 (en) 2009-01-21
BG64707B1 (en) 2005-12-30
EP1027362B1 (en) 2005-06-29
EP1027362A1 (en) 2000-08-16
PL340290A1 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
CA2316919A1 (en) Novel macrolides
HRP20060275B1 (en) 6-0-supstituted ketolides having antibacterial activity
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
AP9801253A0 (en) 9-Oxime erythromycin derivatives.
BR9813317A (en) Compound, pharmaceutical composition for treating bacterial infections, and processes for treating bacterial infections, and for preparing a compound
DE69631609D1 (en) Tricyclische erythromycinderivate
TR200000620T2 (en) 6.9-Bridged erythromycin derivatives.
CA2351429A1 (en) 13-membered azalides and their use as antibiotic agents
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
TW427906B (en) Antifungal compositions
UA42733C2 (en) Bis-naphthalimide derivatives and pharmaceutically acceptable acid addition salts thereof, pharmaceutical composition containing them showing cytotoxic activity
BR9708929A (en) Compound pharmaceutical composition and processes for controlling bacterial infection in a mammal and for preparing macrolide compounds
WO1999011651A3 (en) 3-descladinose 6-o-substituded erythromycin derivatives
CA2380455A1 (en) 9a-azalides with antibacterial activity
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
CA2290421A1 (en) Multicyclic erythromycin derivatives
MY133222A (en) Method of treating glaucoma and ischemic retinopathy
CA2563965A1 (en) 6-0-substituted ketolides having antibacterial activity